| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-273
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-273
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D205-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D205-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate |
2000-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36326793f5cd2dd51343c4894ea847a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eb1297a3f7bbf362f5026f9f2a72b00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc7712416ce2e9520d24e3c105333a1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59d48d672786eb454754cd47b3a8196b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62abc0930d4d686e43c2f77733a8cc9f |
| publicationDate |
2002-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1183238-A1 |
| titleOfInvention |
Metabotropic glutamate receptor antagonists |
| abstract |
This invention relates to a novel series of compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of stimulation of the human Group I metabotropic glutamate receptors, especially those designated as mGluR5. This invention also provides methods for the treatment of such disorders, as well as pharmaceutical formulations which employ the novel metabotropic glutamate receptor antagonists to which the present invention relates. |
| priorityDate |
1999-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |